Management of Diabetic Kidney Disease

The global prevalence of chronic kidney disease (CKD) from all causes is increasing with parallel increases in the number of people undergoing renal replacement therapy and increases in costs of care. The pathophysiology of diabetic kidney disease (DKD) is complex and heterogeneous. Clinical trials have shown benefits in renal outcomes with drugs acting on the renin-angiotensin-aldosterone system (RAAS) axis, as well as sodium-glucose cotransporter 2 (SGLT2) inhibitors, and GLP1RA. In this manuscript we review the management of diabetic kidney disease.